Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.007 | 0.4539 | 0.5 | |
Schistosoma mansoni | jun-related protein | 0.0073 | 0.5236 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0089 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0054 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0054 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0054 | 0 | 0.5 |
Echinococcus granulosus | jun protein | 0.0089 | 1 | 1 |
Echinococcus multilocularis | jun protein | 0.0089 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.007 | 0.4539 | 0.4539 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0054 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0089 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 0.9303 | 1 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0054 | 0 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0054 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0073 | 0.5236 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0054 | 0 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0054 | 0 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0054 | 0 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0054 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.